D. E. Shaw & Co., Inc. Avrobio, Inc. Transaction History

D. E. Shaw & Co., Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.68 - $1.11 $238,816 - $389,833	-351,201 Reduced 78.25%	97,643 $63,000
Q2 2022 Aug 15, 2022	SELL	$0.75 - $1.33 $24,305 - $43,101	-32,407 Reduced 6.73%	448,844 $413,000
Q1 2022 May 16, 2022	BUY	$1.29 - $4.04 $544,098 - $1.7 Million	421,782 Added 709.25%	481,251 $635,000
Q4 2021 Feb 14, 2022	BUY	$3.45 - $6.05 $205,168 - $359,787	59,469 New	59,469 $229,000
Q3 2020 Nov 16, 2020	SELL	$12.99 - $19.41 $232,962 - $348,098	-17,934 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$12.19 - $22.96 $218,615 - $411,764	17,934 New	17,934 $313,000

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.